Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Email
Dr. Helen Chen, MD

Helen X. Chen, M.D.

  • Associate Branch Chief, Immunooncology
  • NCI Division of Cancer Treatment and Diagnosis (DCTD) Cancer Therapy Evaluation Program (CTEP)
  • Investigational Drug Branch
240-276-6565 |
Scientific Publications

Dr. Helen Chen joined NCI’s Cancer Therapy Evaluation Program (CTEP) in 2000. She currently serves as Associate Chief of Immuno-oncology for the Investigational Drug Branch (IDB), leading activities related to the clinical development of new cancer immunotherapy agents and therapeutic antibodies. Dr. Chen is board-certified in Medical Oncology after completing her Fellowship training at Georgetown University Medical Center in Washington D.C.

  • Updated:
Email